bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

bluebird bio, Inc.

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

bluebird bio is a biotechnology company that develops gene therapies for severe genetic diseases and cancer.

bluebird bio

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

Community guidelines: http://bit.ly/bbbGuidelines

TC BioPharm

Hercules Capital

ARCH Venture Partners

Easton Capital

Third Rock Ventures

TVM Capital

RA Capital Management

ArmaVir Partners

Deerfield Partners

Forbion Capital Partners

California Institute for Regenerative Medicine

Meet Azizi Coleman, Patient and Community Liaison, and member of the bPACE flock. She shares some unique fun facts about herself as well as what inspires her every day as part of the team at bluebird bio.

The flock was thrilled to welcome sickle cell warrior, advocate, and member of the LGBTQ+ community, Andrè Marcel Harris, to the nest for a conversation about the many aspects of Andrè's experience – his race, sexual identity, faith, and more – that intersect and overlap to shape his journey with sickle cell disease. 

Along with sharing his lived experiences, he also visited our lab to meet with some of the minds behind our science and participated in the flock’s Juneteenth celebrations. Warriors like Andrè inspire us to fly higher every day – thank you for joining us at the nest, Andrè!

Holy COW, the flock had a great time at the Cooley's Anemia Foundation Patient-Family Conference! 

It's always an honor connecting with the #betathalassemia community and learning more about how we can better serve people living with beta-thalassemia. And it’s especially fun when our Director of Patient Advocacy, Susan Brisendine, gets the chance to rock her inflatable cow costume at the conference’s costume party! 🐮

The flock had an amazing time at Foundation for Sickle Cell Disease Research’s 18th Annual Sickle Cell Disease Research & Educational Symposium. Our birds were grateful for the opportunity to attend and hear from leaders and members of the #sicklecell community.
 
As Shanna Gillis, Manager of Patient Advocacy, shared: “My first experience at FSCDR was phenomenal! The level of authentic engagement with the community and the thought-provoking educational opportunities were unmatched. I’m looking forward to bringing all my learnings back to the nest so the flock can continue to grow and improve.”

Welcome to our bPACE birds’ series! 

Did you know we have a specific flock of birds, bPACE, who work to educate the communities we serve about gene therapy? 

Meet Phill Okwo, Director of Patient and Community Education, one of our birds who soars to great heights. 

Learn more about Phill and what inspires him.

Last week, members of the flock migrated to #BIO2024. Here are some of the highlights of our team flying high:
➟ We shared perspective (and some hard-won lessons!) from a decade of gene therapy leadership during a fireside chat with Andrew Dunn from Endpoints News.
➟ We facilitated a conversation among pioneers from across the healthcare ecosystem who are blazing the trail for gene therapy access in the commercial setting.
➟ We took a training hike for Luke Timmerman's Timmerman Traverse with others from across the industry who are committed to paying it forward.
➟ We heard BIO International Convention’s new CEO John F. Crowley talk about his vision for the industry and the importance of keeping patients at the heart of our work, specifically sharing the New York Times piece highlighting sickle cell disease gene therapy.
➟ We connected with advocates and other innovators who are committed to changing the world for patients and families.
➟ We celebrated how far we’ve come and all that is ahead – for bluebird, for the field of gene therapy, and for patients and their families.

Metric
Company Name	bluebird bio, Inc.	BridgeBio Pharma	CRISPR Biotech Engineering	Hera BioLabs
Symbol	BLUE
MSH ID	COM:BLUEBIRDBIO	COM:BRIDGEBIOPHARMA	COM:CRISPR-BTE	COM:HERABIOLABS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	GB	US
Stage		Post-IPO Equity		Venture Round
Employee Count	323
Website	bluebirdbio.com	bridgebiopharma.com	crispr-bte.com	herabiolabs.com
LinkedIn	bluebirdbio
Founders

Metric
Market Cap	200.45M
Enterprise Value
Monthly Web Traffic		23.81K	1.41K
Web Traffic Growth		0.19	-0.46
Valuation
Raised Capital		250M	1.07M

Metric
Revenue	29.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-4.03M
EBITDA	-167.16M
Operating Income	-244.26M
Net Income	-211.91M
EPS	-1.93
Diluted EPS	-1.93
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.10
Operating Profit Margin	-5.97
EBITDA Margin	-5.67
Net Profit Margin	-3.61
Return on Equity	-0.29
Return on Assets	-0.13
Return on Capital Employed	-0.30

COM:BLUEBIRDBIO

bluebird bio

Last Close

0.30

22/11 21:00

Market Cap

200.45M

Beta: -

Volume Today

10.33M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.26
P/B Ratio	0.44
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.15
EV Multiple	0.76

Metric
Days Sales Outstanding	386.42
Days Payables Outstanding	302.96
Days Inventory Outstanding	320.30
Operating Cycle	707.83
Cash Conversion Cycle	404.59
Asset Turnover	0.10

Metric
Operating Cash Flow	-235.05M
Free Cash Flow	-239.24M
Cash Flow to Debt	-0.54
Operating Cash Flow/Sales	-3.95
Free Cash Flow Yield	-1.26

Metric
Cash & Equivalents	221.75M
Accounts Receivable	5.04M
Inventory	22.92M
Goodwill	5.65M
Debt to Capitalization	0.88
Debt to Assets	0.49
Current Ratio	1.55
Quick Ratio	1.42

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.73
R&D to Revenue	8.28
SG&A to Revenue